Post kala-azar dermal leishmaniasis: An unresolved mystery

Trends in Parasitology

Volumn 30, Issue 2, 2014, Pages 65-74

  Mukhopadhyay, Debanjan ^a   Dalton, Jane E ^b   Kaye, Paul M ^b   Chatterjee, Mitali ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Antimony; Post kala azar dermal leishmaniasis (PKDL); Regulatory T cells; UV light; Vitamin D

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY GLUCONATE; MILTEFOSINE; PAROMOMYCIN;

GENETIC SUSCEPTIBILITY; HUMAN; MEMORY T LYMPHOCYTE; PATHOGENESIS; POST KALAAZAR DERMAL LEISHMANIASIS; REINFECTION; REVIEW; ULTRAVIOLET RADIATION; VISCERAL LEISHMANIASIS;

NASO HEXACANTHUS;

ANTIMONY; POST KALA-AZAR DERMAL LEISHMANIASIS (PKDL); REGULATORY T CELLS; UV LIGHT; VITAMIN D;

ANTIMONY; ANTIPROTOZOAL AGENTS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEISHMANIASIS, CUTANEOUS; T-LYMPHOCYTES; ULTRAVIOLET RAYS;

EID: 84892960979     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2013.12.004     Document Type: Review

References (75)

1. Antinori S., et al. Post kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome. Br. J. Dermatol. 2007, 157:1032-1036.
2. Ganguly S., et al. Post kala-azar dermal leishmaniasis - an overview. Int. J. Dermatol. 2010, 49:921-931.
3. Desjeux P., Ramesh V. Post kala-azar dermal leishmaniasis: facing the challenge of eliminating kala-azar from South Asia. Kala Azar in South Asia - Current Status and Challenges Ahead 2011, 111-124. Springer. T.K. Jha, E. Noiri (Eds.).
4. Zijlstra E.E., et al. Post kala-azar dermal leishmaniasis. Lancet Infect. Dis. 2003, 3:87-98.
5. Mondal D., Khan M.G. Recent advances in post kala-azar dermal leishmaniasis. Curr. Opin. Infect. Dis. 2011, 24:418-422.
6. Rahman K.M., et al. Increasing incidence of post kala-azar dermal leishmaniasis in a population-based study in Bangladesh. Clin. Infect. Dis. 2010, 50:73-76.
7. Uranw S. Post kala-azar dermal leishmaniasis in Nepal: a retrospective cohort study (2000-2010). PLoS Negl. Trop. Dis. 2011, 5:e1433.
8. Das V.N., et al. Clinical epidemiologic profile of a cohort of post kala-azar dermal leishmaniasis patients in Bihar, India. Am. J. Trop. Med. Hyg. 2012, 86:959-961.
9. Ganguly S., et al. Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes indicate a role for regulatory T cells in Indian post kala-azar dermal leishmaniasis. J. Invest. Dermatol. 2010, 130:1013-1022.
10. Thakur C.P., et al. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Indian J. Med. Res. 2008, 128:38-44.
11. Zijlstra E.E., el-Hassan A.M. Leishmaniasis in Sudan. Post kala-azar dermal leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 2001, 95:S59-S76.
12. Ramesh V., Mukherjee A. Post kala-azar dermal leishmaniasis. Int. J. Dermatol. 1995, 34:85-91.
13. Salotra P., Singh R. Challenges in the diagnosis of post kala-azar dermal leishmaniasis. Indian J. Med. Res. 2006, 123:295-310.
14. Ramesh V. Treatment of post kala-azar dermal leishmaniasis. Int. J. Dermatol. 1994, 33:153-156.
15. Croft S.L. PKDL - a drug related phenomenon?. Indian J. Med. Res. 2008, 128:100-111.
16. Sundar S., et al. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 2002, 347:1739-1746.
17. Das V.N., et al. Development of post kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis. Am. J. Trop. Med. Hyg. 2009, 80:336-338.
18. Kumar D., et al. Post kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Ann. Trop. Med. Parasitol. 2009, 103:727-730.
19. Pandey K., et al. Post kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India. J. Clin. Microbiol. 2012, 50:1478-1479.
20. Saha S., et al. IL-10 and TGF-β-mediated susceptibility in kala-azar and post kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J. Immunol. 2007, 179:5592-5603.
21. Mukhopadhyay D., et al. Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis. J. Infect. Dis. 2011, 204:1427-1436.
22. El Fadili K., et al. Modulation of gene expression in human macrophages treated with the anti-leishmania pentavalent antimonial drug sodium stibogluconate. Antimicrob. Agents Chemother. 2008, 52:526-533.
23. Gupta S., et al. Host peroxisomal properties are not restored to normal after treatment of visceral leishmaniasis with sodium antimony gluconate. Exp. Parasitol. 2009, 123:140-150.
24. Vanaerschot M., et al. Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden. PLoS ONE 2011, 6:e23120.
25. Salotra P., et al. Upregulation of surface proteins in Leishmania donovani isolated from patients of post kala-azar dermal leishmaniasis. Microbes Infect. 2006, 8:637-644.
26. McCall L.I., Matlashewski G. Involvement of the Leishmania donovani virulence factor A2 in protection against heat and oxidative stress. Exp. Parasitol. 2012, 132:109-115.
27. Rogers M.B., et al. Chromosome and gene copy number variation allow major structural change between species and strains of Leishmania. Genome Res. 2011, 21:2129-2142.
28. Ismail A., et al. The pathogenesis of post kala-azar dermal leishmaniasis from the field to the molecule: does ultraviolet light (UVB) radiation play a role?. Med. Hypotheses 2006, 66:993-999.
29. Clydesdale G.J., et al. Ultraviolet light induced injury: immunological and inflammatory effects. Immunol. Cell Biol. 2001, 79:547-568.
30. Amerio P., et al. UV induced skin immunosuppression. Anti-Inflamm. Anti-Allergy Agents Med. Chem. 2009, 8:3-13.
31. Hart P.H., et al. Modulation of the immune system by UV radiation: more than just the effects of vitamin D?. Nat. Rev. Immunol. 2011, 11:584-596.
32. Noonan F.P., De Fabo E.C. Immunosuppression by ultraviolet B radiation: initiation by urocanic acid. Immunol. Today 1992, 13:250-254.
33. Gibbs N.K., Norval M. Urocanic acid in the skin: a mixed blessing?. J. Invest. Dermatol. 2011, 131:14-17.
34. Weiss J.M., et al. Low-dose UVB radiation perturbs the functional expression of B7.1 and B7.2 co-stimulatory molecules on human Langerhans cells. Eur. J. Immunol. 1995, 25:2858-2862.
35. Simon J.C., et al. Distorted antigen-presenting function of Langerhans cells induced by tumor necrosis factor α via a mechanism that appears different from that induced by ultraviolet B radiation. Photodermatol. Photoimmunol. Photomed. 1991, 8:190-194.
36. Musa A.M., et al. The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immunological and prognostic features. Ann. Trop. Med. Parasitol. 2002, 96:765-772.
37. Ansari N.A., et al. Interferon (IFN)-γ, tumor necrosis factor-α, interleukin-6, and IFN-γ receptor 1 are the major immunological determinants associated with post kala azar dermal leishmaniasis. J. Infect. Dis. 2006, 194:958-965.
38. Ismail A., et al. Pathology of post kala-azar dermal leishmaniasis: a light microscopical, immunohistochemical, and ultrastructural study of skin lesions and draining lymph nodes. J. Cutan. Pathol. 2006, 33:778-787.
39. Baeke F., et al. Vitamin D: modulator of the immune system. Curr. Opin. Pharmacol. 2010, 10:482-496.
40. Griffin M.D., et al. Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu. Rev. Nutr. 2003, 23:117-145.
41. Whitcomb J.P., et al. The role of vitamin D and vitamin D receptor in immunity to Leishmania major infection. J. Parasitol. Res. 2012, 2012:134645.
42. Martinez F.O., et al. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 2009, 27:451-483.
43. Katara G.K., et al. Foxp3 and IL-10 expression correlates with parasite burden in lesional tissues of post kala azar dermal leishmaniasis (PKDL) patients. PLoS Negl. Trop. Dis. 2011, 5:e1171.
44. Ehrchen J., et al. Vitamin D receptor signaling contributes to susceptibility to infection with Leishmania major. FASEB J. 2007, 21:3208-3218.
45. Mendonça M.G., et al. Persistence of Leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure?. J. Infect. Dis. 2004, 189:1018-1023.
46. Aebischer T., et al. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect. Immun. 1993, 61:220-226.
47. Schubach A., et al. Cutaneous scars in American tegumentary leishmaniasis patients: a site of Leishmania (Viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cure. Am. J. Trop. Med. Hyg. 1998, 58:824-827.
48. Dey A., Singh S. Genetic heterogeneity among visceral and post Kala-Azar dermal leishmaniasis strains from eastern India. Infect. Genet. Evol. 2007, 7:219-222.
49. + memory T cells following Leishmania infection. Trends Parasitol. 2005, 21:347-350.
50. Desjeux P. Global control and Leishmania HIV co-infection. Clin. Dermatol. 1999, 17:317-325.
51. Engwerda C.R., Kaye P.M. Organ-specific immune responses associated with infectious disease. Immunol. Today 2000, 21:73-78.
52. Ismail A., et al. Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile. J. Pathol. 1999, 189:615-622.
53. Rathi S.K., et al. Lesional T-cell subset in post kala-azar dermal leishmaniasis. Int. J. Dermatol. 2005, 44:12-13.
54. Okwor I., Uzonna J. Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies. Immunol. Res. 2008, 41:123-136.
55. Diaz N.L., et al. Intermediate or chronic cutaneous leishmaniasis: leukocyte immunophenotypes and cytokine characterisation of the lesion. Exp. Dermatol. 2002, 11:34-41.
56. Tuon F.F., et al. The expression of TLR9 in human cutaneous leishmaniasis is associated with granuloma. Parasite Immunol. 2010, 32:769-772.
57. Rathi S.K., et al. Post kala-azar dermal leishmaniasis: a histopathological study. Indian J. Dermatol. Venereol. Leprol. 2005, 71:250-253.
58. Lipoldová M., Demant P. Genetic susceptibility to infectious disease: lessons from mouse models of leishmaniasis. Nat. Rev. Genet. 2006, 7:294-305.
59. Foote S.J., Handman E. Genetics of murine leishmaniasis. Brief. Funct. Genomic Proteomic 2005, 4:270-276.
60. Blackwell J.M. Genetic susceptibility to leishmanial infections: studies in mice and man. Parasitology 1996, 112:S67-S74.
61. Consortium LeishGEN., et al. Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. Nat. Genet. 2013, 45:208-213.
62. Mohamed H.S., et al. Genetic susceptibility to visceral leishmaniasis in The Sudan: linkage and association with IL4 and IFNGR1. Genes Immun. 2004, 4:351-355.
63. Salih M.A., et al. IFNG and IFNGR1 gene polymorphisms and susceptibility to post kala-azar dermal leishmaniasis in Sudan. Genes Immun. 2007, 8:75-78.
64. Alexander J., Brombacher F. T helper1/T helper2 cells and resistance/susceptibility to Leishmania infection: is this paradigm still relevant?. Front. Immunol. 2012, 3:80.
65. Farouk S., et al. Interleukin 10 gene polymorphisms and development of post kala-azar dermal leishmaniasis in a selected Sudanese population. Public Health Genomics 2010, 13:362-367.
66. Gasim S., et al. High levels of C-reactive protein in the peripheral blood during visceral leishmaniasis predict subsequent development of post kala-azar dermal leishmaniasis. Acta Trop. 2000, 75:35-38.
67. Kilpatrick D.C., Chalmers J.D. Human L-ficolin (ficolin-2) and its clinical significance. J. Biomed. Biotechnol. 2012, 2012:138797.
68. Assaf A., et al. Genetic evidence of functional ficolin-2 haplotype as susceptibility factor in cutaneous leishmaniasis. PLoS ONE 2012, 7:e34113.
69. Alonso D.P., et al. Genotypes of the mannan-binding lectin gene and susceptibility to visceral leishmaniasis and clinical complications. J. Infect. Dis. 2007, 195:1212-1217.
70. Blackwell J.M., et al. SLC11A1 (formerly NRAMP1) and disease resistance. Cell. Microbiol. 2001, 3:773-784.
71. Mohamed H.S., et al. SLC11A1 (formerly NRAMP1) and susceptibility to visceral leishmaniasis in The Sudan. Eur. J. Hum. Genet. 2004, 12:66-74.
72. Blackwell J.M., et al. Genetics and visceral leishmaniasis in the Sudan: seeking a link. Trends Parasitol. 2004, 20:268-274.
73. Ganguly S., et al. Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post kala-azar dermal leishmaniasis. J. Infect. Dis. 2008, 197:1762-1771.
74. Ansari N.A., et al. Evidence for involvement of TNFR1 and TIMPs in pathogenesis of post kala-azar dermal leishmaniasis. Clin. Exp. Immunol. 2008, 154:391-398.
75. Katara G.K., et al. Evidence for involvement of Th17 type responses in post kala azar dermal leishmaniasis (PKDL). PLoS Negl. Trop. Dis. 2012, 6:e1703.